Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Effect of Dulaglutide on Blood Pressure and Heart Rate in Type 2 Diabetes
NCT01149421Phase 2Completed
- Sponsor
- Eli Lilly and Company
- Start
- Jun 2010
- Primary completion
- Sep 2011
- Modality
- Recombinant Proteins and Enzymes
- Countries
- 8
01
Overview
Phase 2, randomised, double-blind trial of dulaglutide biosimilar 14028 injection in type 2 diabetes mellitus (T2DM) (3 arms), sponsored by Eli Lilly and Company. Primary endpoint: Change From Baseline to 16 Weeks in Mean 24-hour Systolic Blood Pressure (SBP). Started Jun 2010; status: completed.
02
Drugs
dulaglutide biosimilar 14028 injection
03
Conditions
type 2 diabetes mellitus (T2DM)
Beyond the preview
Go deeper on NCT01149421.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT01149421.